Darryl Sleep on Engasertib: This is a Significant Step Forward for Patients Dealing with HHT
Darryl Sleep, Former Head Global Public Health at Amgen, BioPharma Executive, reposted from Vaderis Therapeutics AG on LinkedIn:
”This is a significant step forward for patients dealing with Hereditary Hemorrhagic Telangiectasia (HHT), the second most common inherited bleeding disorder.
This is the result of collaboration and partnership across the entire HHT community of researchers, academics, patient advocacy, patients and caregivers with a focused, targeted approach to address a major medical need for patients who do not have an approved therapeutic.
Vaderis and our partners are moving forward with urgency and a commitment to patients to initiate the Phase 3 HEROIC study in 2026.
Patients living with HHT can’t wait for effective therapies to improve their lives.”
Quoting Vaderis Therapeutics AG‘s post:
”Moving Forward Together for the HHT Community
We’re honored to share that The New England Journal of Medicine has published results from our clinical study of engasertib (VAD044) in Hereditary Hemorrhagic Telangiectasia (HHT).
This milestone reflects the dedication of patients, families, and advocacy partners who made this research possible.
While more work lies ahead, these published findings strengthen our commitment to developing a potential new treatment option for a community that has long gone without approved therapies.
As we prepare for the Phase 3 HEROIC study in 2026, we remain focused on bringing hope and meaningful progress to people living with HHT.
Read the full press release.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 14:36Aremu David: Solving Tic-Tac-Toe in 7ms: How I Built Nine
-
Sep 5, 2026, 13:05Sheharyar Raza: Threshold-Based Transfusion in Sickle Cell Disease
-
Sep 5, 2026, 12:34Stijn Wigerinck: A Practical Roadmap for Eosinophilia and Hypereosinophilia
-
Sep 5, 2026, 11:51Alejandro González Veliz: Why Secondary Prevention Matters After PCI
-
Sep 5, 2026, 11:39Julie Rayes: Sepsis Rewrites the Role of Mast Cells in Thrombosis
-
Sep 5, 2026, 11:30Shirley D’Sa: Chemoimmunotherapy in Cold Agglutinin Disease and WM-Associated CAS
-
Sep 5, 2026, 11:29Dilini Christina Ranasinghe: An Exception to the ‘Universal Donor’ – Bombay (Oh)
-
Sep 5, 2026, 11:10Amanda Stahl: Integrating Psychosocial Care Into Comprehensive Hemophilia Treatment
-
Sep 5, 2026, 10:23Danny Hsu: Honouring Rob Bird’s Career and Impact in Haematology